gms | German Medical Science

21st Annual Meeting of the German Retina Society and 8th Symposium of the International Society of Ocular Trauma (ISOT)

German Retina Society
International Society of Ocular Trauma

19.06. - 22.06.2008, Würzburg

Photodynamic Therapy with Verteporfin combined with Intravitreal Injection of Ranibizumab for Occult and Classic CNV in AMD

Meeting Abstract

  • Mathias Maier - München/Germany
  • N. Feucht - München/Germany
  • B. Fiore - München/Germany
  • C. Winkler - München/Germany
  • C. von Mohrenfels - München/Germany
  • P. Kook - München/Germany
  • C. Fegert - München/Germany
  • C.P. Lohmann - München/Germany

Retinologische Gesellschaft. International Society of Ocular Trauma. 21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem 8. Symposium der International Society of Ocular Trauma. Würzburg, 19.-22.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocISOTRG2008V120

The electronic version of this article is the complete one and can be found online at:

Published: June 18, 2008

© 2008 Maier et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Purpose: To discuss the effect and outcome of a combined photodynamic therapy and intravitreal injection of ranibizumab (0.5 mg) in occult CNV with recent disease progression and in classic choroidal neovascularisation (CNV) due to AMD.

Methods: In a pilot study in 25 patients (18 classic, 7 occult CNV) intravitreal injection of ranibizumab was administered within 12 to 24 hours after standard PDT , followed by 2 injections of ranibizumab after 1 and 2 months. Before, 3 and 6 month after treatment visual acuity, OCT examinations (retinal thickness) and fluorescein angiography were performed.

Results: Mean visual acuity was significantly improved compared to baseline. (VA baseline 20/80, after 3 month 20/50, and 20/63 after 6 month). We found no choroidal hypoperfusion and no RPE rip. OCT-findings and fluorescein angiography in patients with occult and classic choroidal neovascularisation 3 and 6 month after combination therapy showed a reduced retinal thickness (baseline: 241µm, after 3 month: 205µm and after 6 month 232µm) and reduction of leakage compared to baseline.

Conclusions: Photodynamic therapy combined with injection of intravitreal ranibizumab was well tolerated and tends to be more effective compared to ranibizumab mono-therapy. Our short term results are very promising. Further studies are necessary to show the long term effect of PDT and Anti-VEGF combination therapy.